Emerging research suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , could provide a significant development for weight loss . Early human trials have indicated substantial losses in abdominal fat , conceivably outperforming other weight-loss therapies . Nevertheless , more evaluation is